PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study
- PMID: 27232854
- PMCID: PMC5507093
- DOI: 10.4103/1008-682X.180798
PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study
Abstract
Prostate cancer is the second most common male cancer, with half of all patients going on to develop metastases. To better identify patients at high risk for prostate cancer progression and reduce prostate cancer-related mortality, improved prognostic factors are required. In this study, we used immunohistochemistry (IHC) to determine the prognostic values of multiple tissue biomarkers in hormone-naοve prostatectomy specimens of prostate cancer. Using 510 prostatectomy specimens collected between 2002 and 2012, IHC analysis was performed for Cerb-2, Cyclin D1, VEGF, EGFR, Rb, PSCA, p53, Bcl-2, Cox-2, PMS2, and Ki-67 on formalin-fixed paraffin-embedded sections. The Cox proportional hazard model was used to determine the predictive risk factors for biochemical recurrence (BCR) of prostate cancer. During a median 44-month follow-up, 128 (25.1%) patients developed BCR. A multivariate regression analysis revealed that Ki-67 (hazard ratio [HR]: 1.60, P = 0.033), PSCA (HR: 0.42, P < 0.001), and Cox-2 (HR: 2.05, P = 0.003) were the only significant prognostic tissue markers of BCR. Resection margin status (HR: 1.67, P = 0.010), pathologic pT0/1/2 stage (vs pT3/4; HR: 0.20, P = 0.002), preoperative PSA levels (HR: 1.03, P < 0.001), biopsied (HR: 1.30, P = 0.022) and pathologic (HR: 1.42, P = 0.005) Gleason scores, and prostate size (HR: 0.97, P = 0.003) were significant clinicopathologic factors. The expression of Ki-67, PSCA, and Cox-2 biomarkers along with other clinicopathologic factors were prognostic factors for BCR in patients with clinically localized prostate cancer following radical prostatectomy.
Figures

Similar articles
-
Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy.Histopathology. 2016 Apr;68(5):673-9. doi: 10.1111/his.12809. Epub 2015 Oct 13. Histopathology. 2016. PMID: 26272590
-
The Quantified Level of Circulating Prostate Stem Cell Antigen mRNA relative to GAPDH Level Is a Clinically Significant Indictor for Predicting Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.Biomed Res Int. 2015;2015:292454. doi: 10.1155/2015/292454. Epub 2015 Oct 7. Biomed Res Int. 2015. PMID: 26527100 Free PMC article.
-
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.Int J Cancer. 2006 Sep 1;119(5):1082-7. doi: 10.1002/ijc.21749. Int J Cancer. 2006. PMID: 16557596
-
Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.Eur Urol. 1999;35(5-6):399-407. doi: 10.1159/000019916. Eur Urol. 1999. PMID: 10325496 Review.
-
An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer.J Surg Oncol. 1998 Jan;67(1):33-7. doi: 10.1002/(sici)1096-9098(199801)67:1<33::aid-jso7>3.0.co;2-n. J Surg Oncol. 1998. PMID: 9457254 Review.
Cited by
-
Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.World J Urol. 2018 Sep;36(9):1495-1500. doi: 10.1007/s00345-018-2290-y. Epub 2018 Apr 20. World J Urol. 2018. PMID: 29679140
-
LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.Exp Ther Med. 2022 Jul 8;24(3):563. doi: 10.3892/etm.2022.11500. eCollection 2022 Sep. Exp Ther Med. 2022. PMID: 36034756 Free PMC article.
-
Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial.BMC Cancer. 2018 Jan 10;18(1):64. doi: 10.1186/s12885-017-3979-9. BMC Cancer. 2018. PMID: 29321047 Free PMC article. Clinical Trial.
-
Changes in immunophenotypes after neoadjuvant endocrine therapy for prostate cancer and their clinical significance.Heliyon. 2024 Jul 26;10(15):e34864. doi: 10.1016/j.heliyon.2024.e34864. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170268 Free PMC article.
-
Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.Pathol Oncol Res. 2020 Apr;26(2):1049-1056. doi: 10.1007/s12253-019-00659-4. Epub 2019 Apr 15. Pathol Oncol Res. 2020. PMID: 30989489 Free PMC article.
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
-
- Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995;45:831–8. - PubMed
-
- Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395–406. - PubMed
-
- Gleason DF, Mellinger GT Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging 1974. J Urol. 2002;167(2 Pt 2):953–8. - PubMed
-
- Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–90. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous